| Literature DB >> 35082907 |
Yufan Wu1, Zhuxian Wang1, Qunqun Du1, Zhaoming Zhu1, Tingting Chen1, Yaqi Xue1, Yuan Wang1, Quanfu Zeng1, Chunyan Shen1, Cuiping Jiang1, Li Liu1, Hongxia Zhu2, Qiang Liu1.
Abstract
Glycyrrhizae Radix et Rhizoma is the most frequently prescribed natural medicine in China and has been used for more than 2,000 years. The flavonoids of licorice have garnered considerable attention in recent decades due to their structural diversity and myriad pharmacological effects, especially as novel therapeutic agents against inflammation and cancer. Although many articles have been published to summarize different pharmacological activities of licorice in recent years, the systematic summary for flavonoid components is not comprehensive. Therefore, in this review, we summarized the pharmacological and mechanistic data from recent researches on licorice flavonoids and their bioactive components.Entities:
Year: 2022 PMID: 35082907 PMCID: PMC8786487 DOI: 10.1155/2022/9523071
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Pharmacological activities of licorice flavonoids.
Figure 2(a) Flavanone, flavone, flavonol, and chalcone structure from licorice. (b) Isoflavone, isoflavanone, isoflavan, and isoflavene structure from licorice.
The anti-inflammatory properties of licorice flavonoids in vitro.
| Compounds | Dose | Inflammation | Cell line/tissue | Inhibition | References |
|---|---|---|---|---|---|
| Licochalcone A | 5–20 | LPS-induced inflammatory reactions | RAW 264.7 cell | Reduced the concentration of TNF- | [ |
| 3 and 10 | LPS-induced inflammatory reactions | RAW 264.7 cell | Dose-dependently inhibited LPS-induced ROS production and reduced the generation of NO, IL-6, and PGE2 | [ | |
| 15 nM | IL-1 | Normal human dermal fibroblasts | Exhibited the 50% inhibition of COX-2-dependent PGE2 production | [ | |
| 5–20 | IL-1 | Primary chondrocytes | Inhibited PGE2, NO, iNOS, COX-2, matrix metalloproteinase-1 (MMP-1), MMP-13, and MMP-3 production in chondrocytes | [ | |
| Licochalcone C | 50 | LPS- (10 | Human myeloid leukemia mononuclear cell (THP-1) | Attenuated inflammatory response by diminishing the expression and activity of iNOS, by modulating extracellular O2− generation and by restraining the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) | [ |
| Isoliquiritigenin | 2.5–10 | LPS- (0.1 | J774A.1 murine macrophage cell line | Inhibited NO, IL-1 | [ |
| 10 | 2,4-Dinitrochlorobenzene (DNCB) induced atopic dermatitis | THP-1 cell line | Suppressed the differentiation of CD54 and CD86 and restrained the activation of extracellular signal-regulated kinase (ERK) and p38- | [ | |
| Glabridin | 5–10 | LPS (0.1 | J774A.1 murine macrophage cell line | Moderate inhibition in NO levels with a maximum inhibition of 33% at the highest tested concentration | [ |
| 5–20 | LPS (1 | HaCaT cell line | At 20 | [ | |
| 1–10 | TNF- | MC3T3-E1 cells | The release of PGE2 and the increase of NO in osteoblasts were decreased significantly | [ | |
| Liquiritin | 50 and 100 | LPS (100 ng/mL) stimulated microglial cell model | Murine BV2 cell line | Inhibited the increase of NO and proinflammatory mediators iNOS, COX-2, IL-1 | [ |
| Liquiritigenin | 50 and 100 | LPS- (100 ng/mL) induced microglial cell model | Murine BV2 cell line | Suppressed the augment of NO and proinflammatory mediators COX-2, iNOS, IL-1 | [ |
| 20 and 40 | IL-1 | Chondrocytes from 1-week-old Sprague-Dawley rats | Inhibited the IL-1 | [ | |
| Licoricidin | 0.5–1 | LPS-stimulated secretion of cytokines and MMPs by human monocyte-derived macrophages | Human monoblastic leukemia cell line | Inhibited the secretion of IL-6, chemokine ligand 5, and MMP-7, MMP-8, and MMP-9 | [ |
The anti-inflammatory properties of licorice flavonoids in vivo.
| Compounds | Dose and administration | Inflammation tissues/diseases | Animal | Outcomes | References |
|---|---|---|---|---|---|
| Total flavonoids | 50 and 100 mg/kg once a day for 10 weeks (i.g.) | Azoxymethane/dextran sulfate sodium (AOM/DSS) stimulated colonic inflammation | Female C57BL/6 mice weighing 16–18 g | Greatly suppressed colitis and colorectal tumorigenesis by suppressing the production of inflammatory cytokines and phosphorylation | [ |
| 1.56 g crude drugs per kilogram per day for 3 weeks (i.g.) | Arthritis induced by injection of complete Freund's adjuvant (CFA) | Sprague-Dawley (SD) rats (200 ± 20 g) | Exhibited therapeutic effects on acute inflammation, chronic inflammation, and inflammatory pain and reduced IL-1 | [ | |
| 3–30 mg/kg (i.g.) for 5 times with an interval of 6 h before LPS instillation and for 2 times with an interval of 8 h after LPS instillation | LPS (2 mg/ml) induced acute inflammation of lung | ICR mice | Significantly attenuated LPS-induced pulmonary inflammation by suppressing inflammatory cells infiltration and inflammatory mediator release and reduced neutrophil-mediated oxidative injury | [ | |
| 500 and 250 mg/kg (i.g.) with 40 min before | 1% (w/v) | SD rats (180–220 g) | Significantly ameliorated edema and reduced the expression of TNF- | [ | |
| Licochalcone A | 20, 40, and 80 mg/kg (i.p.) at 1 h prior to LPS administration/1 h after LPS challenge | LPS-induced lung injury/acute kidney | BALB/c mice/female C57BL/6 mice | Attenuated lung/kidney histopathologic changes and inhibited the production of TNF- | [ |
| 50 mg/kg (i.p.) at 1 h before OVA challenges on days 25–27 | Ovalbumin (OVA) stimulated inflammation on noninfectious asthma | Female BALB/c mice, weighing about 16–18 g | Inhibited T-helper type 2 cytokines like IL-4, IL-13, and IL-5 in bronchoalveolar lavage fluid and decreased serum levels of OVA-specific IgG and IgE | [ | |
| Isoliquiritigenin | 20 mg/kg (i.p.) administered at 30 min, 12 h, and 24 h prior to LPS treatment/5–20 mg/kg given 1 h before LPS challenge | LPS-induced neuroinflammation/acute lung injury | Male Wistar rats/BALB/c mice | Reversed LPS-induced increase in expression of TNF- | [ |
| Treated with 1% isoliquiritigenin on dorsal skin daily from day 6 to day 18 | Repetitive application of DNCB-induced atopic dermatitis-like skin lesion | 6–8-week-old BALB/c mice | Suppressed the IgE and Th2 cytokines increase in blood and inhibited the expressions of IL-6, TNF- | [ | |
| Gavaged 7.5–75 mg/kg at 24 hours and 1 h prior to indomethacin challenge | Indomethacin (10 mg/kg) induced small intestinal damage | Wild-type male C57BL/6 mice (7-week-old) | Reversed indomethacin-induced increase in cleaved caspase-1 and mature IL-1 | [ | |
| Glabridin | Glabridin (10, 30, and 50 mg/kg/d) pretreated on shaved back for 7 days | Imiquimod-induced psoriasis-like inflammation | BALB/c mice averagely weighted 20–25 g | Significantly downregulated the mRNA expressions of IL-1 | [ |
| Gavaged 10 or 50 mg/kg/d 1 week before colitis induction and parallel with DSS-feeding for 7 days | Dextran sulfate sodium (DSS, 5%) induced colonic inflammation | Adult male Wistar rats/six-week-old female BALB/c mice | Ameliorated the disruption of the colonic architecture and reduced myeloperoxidase (MPO) activity and production of inflammatory mediators in colon | [ |
Figure 3The main signaling pathway of anti-inflammation of licorice flavonoids.
Anticancer/tumor effects of licorice flavonoid and its active components in experimental models.
| Cancer | Compounds | Dose and administration | Result | References |
|---|---|---|---|---|
| Colon | Isoangustone A | 5–20 | Induced apoptosis in colorectal cancer cells | [ |
| Total flavonoids | Gavaged (50 and 100 mg/kg) once a day for 28 days | Restrained AOM/DSS-induced colitis-associated tumorigenesis, reduced activation of p53 and NF- | [ | |
| Liquiritigenin | 50 and 100 | Exerted significant inhibitory effects on HCT116 colorectal cancer cell invasion and blocked the epithelial-mesenchymal transition (EMT) process | [ | |
| Oral/esophageal squamous | Licochalcone A | 10–40 | Inhibited HN22 and HSC4 oral squamous cell carcinoma cells growth concentration- and time-dependently | [ |
| Licochalcone B | 10–30 | Arrested cell cycle at G1 phase, significantly inhibited cell proliferation, and induced apoptosis in oral squamous cell carcinoma cells | [ | |
| Licochalcone C | 10–30 | Significantly decreased cell viability of esophageal squamous cell carcinoma (ESCC) cells in a dose- and time-dependent manner | [ | |
| Licochalcone H | 10–30 | Induced cell cycle arrest and apoptosis, reduced cell activity, and colony-forming ability in HSC2 and HSC3 oral squamous cell carcinoma cells | [ | |
| Glabridin | 20–80 | Inhibited cell proliferation in human tongue squamous carcinoma cell lines (SCC-9 and SAS) and induced several features of apoptosis | [ | |
| Isoliquiritigenin | 25 and 50 | Induced cell cycle G2/M phase arrest, DNA damage, and apoptosis in oral squamous cell carcinoma cells | [ | |
| Prostate | Licochalcone A | 6.5 and 12.5 | Induced caspase-dependent and autophagy-related cell death in LNCaP cells | [ |
| Isoliquiritigenin | 25 and 50 | Suppressed cell proliferation, induced cell apoptosis, and arrested G2/M cell cycle in human prostate cancer PC-3 and 22RV1 cells | [ | |
| Bladder | Licochalcone A | 10–40 | Exerted antiproliferative effect on human bladder cancer cells and induced G2/M cell cycle arrest and apoptotic cell death | [ |
| Ovary | Isoliquiritigenin | 5 and 10 | Inhibited epithelial-to-mesenchymal transition, migration, and invasion in SKOV3 and OVCAR5 ovarian cancer cells and extended the life span of animals bearing SKOV3/Luc cells consequently | [ |
| Cervix uteri | Liquiritin | 40–80 | Suppressed the migration, invasion, and cloning ability of cervical cancer cells and showed little cytotoxicity to human normal cells | [ |
| Glioma | Licochalcone A | 10–30 | Inhibited glioma cell growth in U87 glioma cell lines and U87 glioma cell xenograft male athymic mice | [ |
| Melanoma | Isoliquiritigenin | 20–80 | Effectively induced apoptosis and inhibited proliferation in mouse melanoma B16F10 cells | [ |
| Uterine leiomyoma | Isoliquiritigenin | 10–40 | Exerted inhibition of estrogen-induced uterine leiomyoma growth both | [ |
| Pleural mesothelioma | Licochalcone A | 10–40 | Induced apoptosis through suppressing Sp1 expression in malignant pleural mesothelioma cell MSTO-211H and H28 | [ |
| Osteosarcoma | Licochalcone A | 20–60 | Inhibited cell proliferation and induced apoptosis in human osteosarcoma cells by reduction of cell viability, activation of caspases, and loss of mitochondrial membrane potentials | [ |
Figure 4The main antitumor signaling pathway of licorice flavonoids.
The antioxidant properties of licorice flavonoids.
| Compounds | Model | Dose and effects | References |
|---|---|---|---|
| Isoliquiritigenin | LPS-induced acute lung injury mice | Treatment with isoliquiritigenin (30 mg/kg) enhanced the production of ROS, MPO, and MDA, ameliorating low expression of GSH and SOD caused by LPS stimulation | [ |
| LPS-induced cognitive impairment rats | Isoliquiritigenin (20 mg/kg) pretreatment appeared antioxidant capacity through reversing the downregulation of SOD and GSH-PX activity and reducing the content of MDA | [ | |
| Streptozotocin (STZ) induced diabetic retinopathy | Isoliquiritigenin (20 mg/kg/day) treatment markedly reduced diabetes-induced lipid peroxidation by 27.8%, upregulated retinal GSH 1.57-fold, and restored total retinal antioxidant capacity 2.15-fold | [ | |
|
| Isoliquiritigenin (50 | [ | |
| Liquiritigenin | Serum deprivation in HepG2, H4IIE, and AML12 cells induced oxidative stress | Mitochondrial dysfunction, oxidative stress like ROS formation, and resultant cell death caused by nutrition deprivation were prohibited by liquiritigenin (100 | [ |
| Citrinin (CTN) induced, oxidative-stress-mediated disruption of embryonic development in mouse blastocysts | CTN-triggered ROS generation for sequent apoptosis and injury of blastocysts was restrained by the preincubation of liquiritigenin (20–40 | [ | |
| Glabridin | Methotrexate (MTX) triggered liver injury | Glabridin (20 or 40 mg/kg) lower oxidative stress stimulated by MTX through upregulation of MDA level, as well as reduction of GSH level and SOD activity | [ |
| Diabetic vascular complications mouse | Glabridin prevented the antiatherogenic capacity of paraoxonase 2 (PON2) by the interaction of glabridin-PON2 that protected PON2 from oxidation | [ | |
| Licochalcone A | HepG2 cell and L-02 cell | Licochalcone A inhibited peroxyl radical-induced oxidation of DCFH to DCF in HepG2 cells in a dose-dependent manner and upregulated protein expression of SOD1, CAT, and GPx1 at 2–8 | [ |
The antibacterial, antiviral, and antiprotozoan effects of licorice flavonoids.
| Effects | Compounds | Microorganism | Dose and effect | References |
|---|---|---|---|---|
| Antibacterial effects | 1-Methoxyficifolinol, licorisoflavan A, and 6,8-diprenylgenistein |
| Showed bactericidal effects at the concentration of ≥4 | [ |
| Flavonoid of |
| The inhibition zones of | [ | |
| Licoricidin and glabridin |
| Licoricidin had an MIC of 6.25 | [ | |
| Flavonoid-rich extract of |
| At minimum inhibitory concentration (MIC) of 100 | [ | |
| Flavonoids of |
| Significantly reduced quorum sensing regulated virulence factors of | [ | |
| Isoliquiritigenin and liquiritigenin | MRSA | MIC of both components exhibited significant anti-MRSA activity (50–100 | [ | |
| Licochalcone A |
| The vegetative cell growth of | [ | |
| Licochalcone A |
| Reduced | [ | |
| Nisin/glabridin, nisin/licoricidin, and nisin/licochalcone A |
| Efficiently restrained the growth of | [ | |
| 6-Aldehydo-isoophiopogonone and liquiritigenin | Multidrug-resistant human bacterial | 6-Aldehydo-isoophiopogonone and liquiritigenin showed activity against | [ | |
| Glabridin | Amphotericin B resistant | At an MIC of 31.25–250 | [ | |
| Liquiritin |
| Suppressed the | [ | |
| Antiviral effects | Echinantin and isoliquiritigenin | Influenza A viruses | Showed strong inhibitory effects on various neuraminidases from influenza viral strains, H1N1, H9N2, novel H1N1 (WT), and oseltamivir-resistant novel H1N1 (H274Y) expressed in 293T cells | [ |
| Licocoumarone, glyasperin C, 2′-methoxyisoliquiritigenin, glycyrin, licoflavonol, and glyasperin D | Rotaviruses, specially G5P [ | The 50% effective inhibitory concentrations (EC50) of the six compounds were 18.7–69.5 | [ | |
| Quercetin of | Herpes simplex virus-1 (HSV-1) | Showed 50% decrease for 10 | [ | |
| Kanzonol Y | Dengue virus (DENV) | Exhibited anti-dengue-virus activity due to the outstanding docking properties with DENV protease, DENV RNA-dependent RNA polymerase, and DENV envelope protein | [ | |
| Isobavachalcone | Porcine reproductive and respiratory syndrome virus (PRRSV) | Had potential anti-PRRSV activity and inhibited PRRSV replication at the postentry stage of PRRSV infection | [ | |
| Antiprotozoan effects | Licochalcone A | Chloroquine-susceptible (3D7) and chloroquine-resistant (Ddz) strains of | Had potent antiplasmodial efficacy against chloroquine-susceptible (3D7) and chloroquine-resistant (Ddz) strains of | [ |
The antihyperglycemic effects of licorice flavonoids.
| Compounds | Dose and administration | Result | References |
|---|---|---|---|
| Isoangustone A | 1–20 mmol/L incubated with human renal mesangial cells (HRMC) for three days | High glucose-inflammatory mesangial hyperplasia and matrix dilation were retarded by the accumulation of type IV collagen, and diabetes-related renal inflammation was reduced by attenuating inflammatory ICAM-1 expression and monocyte chemotactic protein-1 (MCP-1) production in the mesangium | [ |
| Isoliquiritigenin | 1–20 | Prevented mesangial fibrosis and glomerulosclerosis generating into renal failure and end-stage renal diseases through diminishing high glucose-related mesangial matrix accumulation | [ |
| Glabridin | 3T3‐L1 adipocytes incubated with 5–20 | Restored TCDD-descended insulin‐stimulated glucose uptake and production of glucose transporter 4 (GLUT4) and insulin receptor substrate 1 (IRS1) | [ |
| Isoliquiritigenin | 20 mg/kg/day to diabetic rats for 8 weeks | Ameliorated diabetes-induced retinal injury in STZ-induced diabetic rats | [ |
| Liquiritigenin | 4–16 mg/kg liquiritigenin-treated mice after fructose feeding | Reduced fructose-diet-induced lipid accumulation and cardiac fibrosis that exerted protective response in high-fructose-diet-triggered cardiac injury | [ |